Feng Jifeng, Wang Liang, Yang Xun, Chen Qixun
Department of Thoracic Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus) of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, China.
Front Immunol. 2024 Dec 17;15:1456193. doi: 10.3389/fimmu.2024.1456193. eCollection 2024.
The role of immunotherapy in the adjuvant setting seems promising in recent years. As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy (AIT). However, it is unknown if individuals with esophageal squamous cell carcinoma (ESCC) who have received neoadjuvant immunochemotherapy (NICT) followed by radical surgery also require AIT.
A retrospective analysis was performed on the data from patients who underwent NICT and radical surgery for ESCC between 2019 and 2020. To compare disease-free survival (DFS) and overall survival (OS), Kaplan-Meier survival curves were produced. To determine the parameters linked to DFS and OS, a Cox model using hazard ratios (HRs) was completed.
Among the 292 eligible patients, 215 cases with a mean age of 63.3 ± 6.8 years, including 190 (88.4%) men and 25 (11.6%) women, were finally recruited. The percentage of R0 resection was 98.3%. After NICT, 65 (30.2%) patients achieved pathological complete response. AIT was given to 78 (36.3%) patients following radical resection. For all patients, the 3-year DFS and OS were 62.3% and 74.0%, respectively. In terms of 3-year DFS (61.5% vs. 62.8%, P=0.984) or OS (76.9% vs. 72.3%, P=0.384), no statistically significant difference was found between patients with and without AIT. AIT significantly improved survival in patients with ypT+N+ (DFS: 23.9% vs. 38.5%, P=0.036; OS: 37.0% vs. 61.5%, P=0.010), but not in those with ypT0N0 or ypT+N0. It was found that AIT was related to both DFS (HR: 0.297; P<0.001) and OS (HR: 0.321; P=0.001) in patients with ypT+N+.
In ypT+N+ ESCC patients, AIT after NICT followed by radical surgery reduces the recurrence and death, thereby improving the DFS and OS. Randomized controlled trials ought to be conducted to further assess the results of this retrospective investigation.
近年来,免疫疗法在辅助治疗中的作用似乎很有前景。根据CheckMate 577试验的结果,接受新辅助放化疗后仍有残留病理疾病的食管癌(EC)患者应考虑辅助免疫治疗(AIT)。然而,接受新辅助免疫化疗(NICT)后行根治性手术的食管鳞状细胞癌(ESCC)患者是否也需要AIT尚不清楚。
对2019年至2020年间接受NICT和ESCC根治性手术的患者数据进行回顾性分析。为比较无病生存期(DFS)和总生存期(OS),绘制了Kaplan-Meier生存曲线。为确定与DFS和OS相关的参数,完成了使用风险比(HRs)的Cox模型。
在292例符合条件的患者中,最终招募了215例,平均年龄为63.3±6.8岁,其中男性190例(88.4%),女性25例(11.6%)。R0切除率为98.3%。NICT后,65例(30.2%)患者达到病理完全缓解。根治性切除术后,78例(36.3%)患者接受了AIT。所有患者的3年DFS和OS分别为62.3%和74.0%。在3年DFS(61.5%对62.8%,P = 0.984)或OS(76.9%对72.3%,P = 0.384)方面,接受和未接受AIT的患者之间未发现统计学上的显著差异。AIT显著改善了ypT+N+患者的生存期(DFS:23.9%对38.5%,P = 0.036;OS:37.0%对61.5%,P = 0.010),但在ypT0N0或ypT+N0患者中未改善。发现在ypT+N+患者中,AIT与DFS(HR:0.297;P<0.001)和OS(HR:0.321;P = 0.001)均相关。
在ypT+N+的ESCC患者中,NICT后行根治性手术再进行AIT可降低复发率和死亡率,从而改善DFS和OS。应进行随机对照试验以进一步评估这项回顾性研究的结果。